Intec Pharma (NASDAQ:NTEC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday, January 10th.
According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
Other equities analysts have also issued research reports about the company. Oppenheimer set a $15.00 price objective on shares of Intec Pharma and gave the company a “buy” rating in a research report on Monday, December 18th. Maxim Group set a $8.00 price objective on shares of Intec Pharma and gave the company a “buy” rating in a research report on Friday, November 17th. CIBC restated an “outperform” rating and issued a $15.00 price objective (up previously from $10.00) on shares of Intec Pharma in a research report on Thursday, September 21st. Finally, ValuEngine downgraded shares of Intec Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Intec Pharma has an average rating of “Buy” and a consensus target price of $11.20.
Intec Pharma (NASDAQ:NTEC) last issued its quarterly earnings data on Wednesday, November 15th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.06). research analysts expect that Intec Pharma will post -1.35 EPS for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in NTEC. Sectoral Asset Management Inc purchased a new stake in Intec Pharma in the 3rd quarter worth approximately $3,177,000. Pura Vida Investments LLC purchased a new stake in Intec Pharma in the 3rd quarter worth approximately $895,000. Caxton Corp purchased a new stake in Intec Pharma in the 3rd quarter worth approximately $681,000. Finally, Migdal Insurance & Financial Holdings Ltd. grew its stake in Intec Pharma by 5.0% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock worth $2,977,000 after acquiring an additional 25,000 shares during the period. 40.16% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Downgrades Intec Pharma (NTEC) to Hold” was originally published by BBNS and is the sole property of of BBNS. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/intec-pharma-ntec-cut-to-hold-at-zacks-investment-research/1821859.html.
Intec Pharma Company Profile
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.